Loading…
Reported covered position: Counsel, House Energy & Commerce Subcommittee on Telecommunications; Deputy Chief of Staff, Rep. Fred Upton
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
-Abuse Deterrent Formulations of opioid analgesics -Hearings related to prescription drug abuse and prevention -H.R. 5582 Abuse Deterrent Access Act of 2018 -H.R. 6 Support for Patients and Communities Act/Opioid Crisis Response Act
-Abuse Deterrent Formulations of opioid analgesics -Hearings related to prescription drug abuse and prevention -H.R. 5582 Abuse Deterrent Access Act of 2018
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
PURDUE PHARMA LP via PURDUE PHARMA, LP
2019 · fourth_quarter · 4A
Monitor issues releted to substance abuse and prevention.
Monitor issues related to substance abuse and addiction.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Source: Senate LDA
-Abuse Deterrent Formulations of opioid analgesics -Hearings related to prescription drug abuse and prevention -H.R. 5582 Abuse Deterrent Access Act of 2018 -H.R. 6 Support for Patients and Communities Act/Opioid Crisis Response Act
-Abuse Deterrent Formulations of opioid analgesics -Hearings related to prescription drug abuse and prevention -H.R. 5582 Abuse Deterrent Access Act of 2018 -H.R. 6 Support for Patients and Communities Act/Opioid Crisis Response Act
-Abuse Deterrent Formulations of opioid analgesics -Hearings related to prescription drug abuse and prevention -H.R. 5582 Abuse Deterrent Access Act of 2018
-Abuse Deterrent Formulations of opioid analgesics -Hearings related to prescription drug abuse and prevention -H.R. 5582 Abuse Deterrent Access Act of 2018 -H.R. 6 Support for Patients and Communities Act/Opioid Crisis Response Act
-Abuse Deterrent Formulations of opioid analgesics -Hearings related to prescription drug abuse and prevention -H.R. 5582 Abuse Deterrent Access Act of 2018 -H.R. 6 Support for Patients and Communities Act/Opioid Crisis Response Act
-Abuse Deterrent Formulations of opioid analgesics -Hearings related to prescription drug abuse and prevention -H.R. 5582 Abuse Deterrent Access Act of 2018 -H.R. 6 Support for Patients and Communities Act/Opioid Crisis Response Act
-Abuse Deterrent Formulations of opioid analgesics -Hearings related to prescription drug abuse and prevention -H.R. 5582 Abuse Deterrent Access Act of 2018 -H.R. 6 Support for Patients and Communities Act/Opioid Crisis Response Act
-Abuse Deterrent Formulations of opioid analgesics -Hearings related to prescription drug abuse and prevention -H.R. 5582 Abuse Deterrent Access Act of 2018 -H.R. 6 Support for Patients and Communities Act/Opioid Crisis Response Act
2019 · fourth_quarter · Q4
Monitor issues related to substance abuse and addiction.
Monitor issues releted to substance abuse and prevention.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PURDUE PHARMA LP via PURDUE PHARMA, LP
2019 · third_quarter · Q3
Monitor issues releted to substance abuse and prevention.
Monitor issues related to substance abuse and addiction.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PURDUE PHARMA LP via PURDUE PHARMA, LP
2019 · second_quarter · Q2
Monitor issues related to substance abuse and addiction.
Monitor issues releted to substance abuse and prevention.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PURDUE PHARMA LP via PURDUE PHARMA, LP
2019 · first_quarter · Q1
Monitor issues releted to substance abuse and prevention.
Monitor issues related to substance abuse and addiction.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PURDUE PHARMA LP via PURDUE PHARMA, LP
2018 · fourth_quarter · Q4
-Abuse Deterrent Formulations of opioid analgesics -Hearings related to prescription drug abuse and prevention -H.R. 5582 Abuse Deterrent Access Act of 2018 -H.R. 6 Support for Patients and Communities Act/Opioid Crisis Response Act
-Abuse Deterrent Formulations of opioid analgesics -Hearings related to prescription drug abuse and prevention -H.R. 5582 Abuse Deterrent Access Act of 2018 -H.R. 6 Support for Patients and Communities Act/Opioid Crisis Response Act
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PURDUE PHARMA LP via PURDUE PHARMA, LP
2018 · third_quarter · Q3
-Abuse Deterrent Formulations of opioid analgesics -Hearings related to prescription drug abuse and prevention -H.R. 5582 Abuse Deterrent Access Act of 2018 -H.R. 6 Support for Patients and Communities Act/Opioid Crisis Response Act
-Abuse Deterrent Formulations of opioid analgesics -Hearings related to prescription drug abuse and prevention -H.R. 5582 Abuse Deterrent Access Act of 2018 -H.R. 6 Support for Patients and Communities Act/Opioid Crisis Response Act
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PURDUE PHARMA LP via PURDUE PHARMA, LP
2018 · second_quarter · Q2
-Abuse Deterrent Formulations of opioid analgesics -Hearings related to prescription drug abuse and prevention -H.R. 5582 Abuse Deterrent Access Act of 2018
-Abuse Deterrent Formulations of opioid analgesics -Hearings related to prescription drug abuse and prevention -H.R. 5582 Abuse Deterrent Access Act of 2018
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PURDUE PHARMA LP via PURDUE PHARMA, LP
2018 · first_quarter · Q1
-Abuse Deterrent Formulations of opioid analgesics -Hearings related to prescription drug abuse and prevention
-Abuse Deterrent Formulations of opioid analgesics -Hearings related to prescription drug abuse and prevention
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE